Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus

Hepatitis B virus (HBV) infection is the leading cause of cirrhosis worldwide. One effective strategy to prevent recurrence or transmission of HBV infection after liver transplantation exists is prescription of Lamivudine, although it is associated with high resistance rates. Adefovir dipivoxil (AD)...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2005-04, Vol.37 (3), p.1507-1508
Main Authors: Herreros de Tejada Echanojáuregui, A., Moreno Planas, J.M., Rubio González, E., Portero Azorin, F., López Monclús, J., Revilla Negro, J., Lucena de la Poza, J.L., Sánchez Turrión, V., Barrios Peinado, C., Cuervas-Mons Martı́nez, V.
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Aged
Antiviral Agents - therapeutic use
Biological and medical sciences
DNA, Viral - isolation & purification
Drug Resistance, Viral
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Hepatitis B - drug therapy
Hepatitis B virus - drug effects
Human viral diseases
Humans
Immunosuppression - methods
Infectious diseases
Lamivudine - therapeutic use
Liver Transplantation - physiology
Medical sciences
Middle Aged
Organophosphonates - therapeutic use
Retrospective Studies
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Tissue, organ and graft immunology
Viral diseases
Viral hepatitis
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B virus (HBV) infection is the leading cause of cirrhosis worldwide. One effective strategy to prevent recurrence or transmission of HBV infection after liver transplantation exists is prescription of Lamivudine, although it is associated with high resistance rates. Adefovir dipivoxil (AD) is a nucleotide analogue of adenosine that has achieved significant results in virologic, biochemical, and clinical parameters in lamivudine-resistant HBV-infected patients. Between 1990 and 2003 7 adult recipients of ortothopic liver transplants who experienced lamivudine-resistant HBV infection (pretransplantation or posttransplantation) were enrolled in a prospective study to administer AD for 48 weeks. At baseline they showed serum HBV DNA between 2.2 × 10 6 and 1.1 × 10 8 copies/mL. After 48 weeks of AD treatment, the median time-weighted average change in serum HBV DNA (log 10 copies/mL) was −3.19 (SD, 1.65). In 3 patients with HBV, DNA was undetectable (
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2005.02.031